- Home
- Publications
- Publication Search
- Publication Details
Title
Renoprotective Effects of DPP-4 Inhibitors
Authors
Keywords
-
Journal
Antioxidants
Volume 10, Issue 2, Pages 246
Publisher
MDPI AG
Online
2021-02-05
DOI
10.3390/antiox10020246
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy
- (2020) Denis Delić et al. Scientific Reports
- Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects
- (2020) Mitsuhiro Kawakubo et al. Scientific Reports
- Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs
- (2020) Swayam Prakash Srivastava et al. Genes
- Nonproteinuric diabetic kidney disease
- (2020) Masayuki Yamanouchi et al. Clinical and Experimental Nephrology
- Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
- (2020) Vlado Perkovic et al. DIABETES CARE
- Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats
- (2020) Yara M. Aboulmagd et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
- (2020) Lucas Opazo-Ríos et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Interplay of Renin-Angiotensin System and Toll-Like Receptor 4 in the Inflammation of Diabetic Nephropathy
- (2020) Qi Feng et al. Journal of Immunology Research
- Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways
- (2020) Sherihan Salaheldin Abdelhamid Ibrahim et al. LIFE SCIENCES
- A role for NPY-NPY2R signaling in albuminuric kidney disease
- (2020) Abigail C. Lay et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
- (2020) Laurie L. Baggio et al. Nature Communications
- Randomized trial of an intensified, multifactorial intervention in patients with advanced‐stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan)
- (2020) Kenichi Shikata et al. Journal of Diabetes Investigation
- GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
- (2020) Daiji Kawanami et al. Frontiers in Pharmacology
- Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: Preclinical evidences with therapeutic approaches
- (2020) Chetan Ram et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Saxagliptin and Vildagliptin Lowered Albuminuria in Patients with Diabetes and Hypertension Independent on Glycemic Control.
- (2020) Marwa Mohsen et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes.
- (2020) Kohjiro Ueki et al. KIDNEY INTERNATIONAL
- Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases
- (2020) Ayano Kubo et al. BMC Nephrology
- Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect
- (2020) Wei-can Chen et al. Frontiers in Immunology
- Effects of Canagliflozin in Patients with Baseline eGFR
- (2020) George Bakris et al. Clinical Journal of the American Society of Nephrology
- The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
- (2020) Daniel V. O'Hara et al. DIABETES OBESITY & METABOLISM
- An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation
- (2020) Sarmistha Saha et al. MOLECULES
- Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
- (2020) Radica Z. Alicic et al. Nature Reviews Nephrology
- Vitamin D3 potentiates the nephroprotective effects of metformin in a rat model of metabolic syndrome: role of AMPK/SIRT1 activation and DPP-4 inhibition
- (2020) Nehal S. Wahba et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Dipeptidyl Peptidase 4 Inhibition Ameliorates Chronic Kidney Disease in a Model of Salt-Dependent Hypertension
- (2019) Donato Cappetta et al. Oxidative Medicine and Cellular Longevity
- Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
- (2019) Carolyn F. Deacon Frontiers in Endocrinology
- CD26/DPP4 - a potential biomarker and target for cancer therapy
- (2019) Njanja Enz et al. PHARMACOLOGY & THERAPEUTICS
- Mechanisms of GLP-1 receptor–independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy
- (2019) Ahmed A. Hasan et al. KIDNEY INTERNATIONAL
- Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
- (2019) Nordin MJ Hanssen et al. Diabetes & Vascular Disease Research
- Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
- (2019) Keiichiro Matoba et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sitagliptin ameliorates thioacetamide-induced acute liver injury via modulating TLR4/NF-KB signaling pathway in mice
- (2019) Dalia H. El-Kashef et al. LIFE SCIENCES
- The Hepatoprotective Effect of Sitagliptin against Hepatic Ischemia Reperfusion-induced Injury in Rats involves Nrf-2/HO-1 Pathway
- (2019) Seham A. Abdel-Gaber et al. Pharmacological Reports
- Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats
- (2019) Mai M. Helmy et al. Pharmacological Reports
- Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice
- (2019) Yuta Takagaki et al. Scientific Reports
- Dipeptidyl‐peptidase‐4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in Systemic Sclerosis
- (2019) Alina Soare et al. Arthritis & Rheumatology
- Effect of sitagliptin on tubulointerstitial Wnt/β‐catenin signalling in diabetic nephropathy
- (2019) Xiaojun Ren et al. NEPHROLOGY
- Dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin alleviates lipopolysaccharide-induced acute lung injury via regulating the Nrf-2/HO-1 and NF-κB pathways
- (2019) Kai Guo et al. JOURNAL OF INVESTIGATIVE SURGERY
- Saxagliptin mitigates airway inflammation in a mouse model of acute asthma via modulation of NF-kB and TLR4
- (2019) Manar G. Helal et al. LIFE SCIENCES
- The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
- (2018) Keizo Kanasaki CLINICAL SCIENCE
- Relationship Between the Brain Natriuretic Peptide (BNP) Level and Prognosis of Diabetic Nephropathy with Microalbuminuria: A 7-Year Follow-Up Study
- (2018) Naoto Seki et al. HORMONE AND METABOLIC RESEARCH
- Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
- (2018) Giuseppe Coppolino et al. PHARMACOLOGICAL RESEARCH
- Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes
- (2018) Netanya Y. Spencer et al. PLoS One
- Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk
- (2018) Benjamin M. Scirica et al. JAMA Cardiology
- Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and reno-protection in type 2 diabetic patients with diabetic kidney disease
- (2018) Munehiro Kitada et al. Journal of Diabetes Investigation
- Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition
- (2018) Elodie M. Varin et al. Cell Metabolism
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Protein kinase C and protein kinase A are involved in the protection of recombinant human glucagon‐like peptide‐1 on glomeruli and tubules in diabetic rats
- (2018) Weiqin Yin et al. Journal of Diabetes Investigation
- Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II–Induced Cardiac Diastolic Dysfunction in Male Mice
- (2017) Scott M Brown et al. ENDOCRINOLOGY
- Regulation of Dipeptidyl Peptidase-4, its Substrate Chemokines, and Their Receptors in Adipose Tissue of ob/ob Mice
- (2017) Jihoon Shin et al. HORMONE AND METABOLIC RESEARCH
- A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment
- (2017) Antonio Chacra et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
- (2017) Daiji Kawanami et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes
- (2017) Lea Duvnjak et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
- (2017) Ahmed A Hasan et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
- (2017) Masanori Hirose et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
- (2017) Koichiro Homma et al. Drugs in research & development
- Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial
- (2017) Kohjiro Ueki et al. Lancet Diabetes & Endocrinology
- Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway
- (2017) Esther Civantos et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition
- (2016) Sen Shi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury
- (2016) Yuki Tanaka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus
- (2016) Yu. S. Gavrilova et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization
- (2016) Fen Zhuge et al. DIABETES
- Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study
- (2016) Tianpeng Zheng et al. Diabetes & Vascular Disease Research
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease
- (2016) Hiroyuki Kamiya Hemodialysis International
- Incretin-Based Therapy for Diabetes
- (2016) Greer Waldrop et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy
- (2016) Oleg Tsuprykov et al. KIDNEY INTERNATIONAL
- Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
- (2016) Satoru Takashima et al. KIDNEY INTERNATIONAL
- Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes
- (2016) Muralikrishna Gangadharan Komala et al. NEPHROLOGY
- Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin
- (2016) Kazuhiko Tsuruya et al. RENAL FAILURE
- Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin
- (2015) Masao Moroi et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Deep Sequencing in Microdissected Renal Tubules Identifies Nephron Segment-Specific Transcriptomes
- (2015) J. W. Lee et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition
- (2015) Sen Shi et al. KIDNEY INTERNATIONAL
- Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: Fact or Fiction?
- (2015) Ivonne Loeffler et al. Cells
- Activation of the Nrf2-ARE Pathway Attenuates Hyperglycemia-Mediated Injuries in Mouse Podocytes
- (2014) Cheng Wang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
- (2014) Peter Vavrinec et al. Current Vascular Pharmacology
- Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
- (2014) Keizo Kanasaki et al. DIABETES
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4
- (2014) Volker Vallon et al. EXPERIMENTAL PHYSIOLOGY
- Relationship Between the Brain Natriuretic Peptide (BNP) Level and Remission of Diabetic Nephropathy with Microalbuminuria: A 3-Year Follow-Up Study
- (2014) N. Seki et al. HORMONE AND METABOLIC RESEARCH
- Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis
- (2014) S. Nakashima et al. HORMONE AND METABOLIC RESEARCH
- Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
- (2014) Catarina Marques et al. MEDIATORS OF INFLAMMATION
- Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study
- (2014) T. Zheng et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat
- (2014) Ravi Nistala et al. Obesity
- Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate 西格列汀通过降低2型糖尿病患者的血压以及估算的肾小球滤过率来减少尿白蛋白/肌酐的比值
- (2014) Isao Kawasaki et al. Journal of Diabetes
- Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study
- (2013) Shigemasa Tani et al. American Journal of Cardiovascular Drugs
- Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes
- (2013) Ryo Kodera et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism
- (2013) D. Wang et al. DIABETES
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
- (2013) Koji Sakata et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1^|^alpha; in type 2 diabetic patients with incipient nephropathy
- (2013) Hiroki Fujita et al. ENDOCRINE JOURNAL
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas
- (2013) Yutaka Seino et al. Journal of Diabetes Investigation
- Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
- (2013) Hiroko Mori et al. Journal of Diabetes Investigation
- Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus
- (2012) Steven G. Coca et al. ARCHIVES OF INTERNAL MEDICINE
- Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
- (2012) Y.-S. Lee et al. DIABETOLOGIA
- Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis
- (2012) Hal E Broxmeyer et al. NATURE MEDICINE
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level
- (2011) Yuji Ishibashi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
- (2010) Sachiko Hattori ENDOCRINE JOURNAL
- GIP and GLP-1, the two incretin hormones: Similarities and differences
- (2010) Yutaka Seino et al. Journal of Diabetes Investigation
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started